These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 23974828)

  • 1. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
    Carlson JJ; Roth JA
    Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of Oncotype DX
    Rabie MA; Rankin A; Burger A; Youssef M
    Ann R Coll Surg Engl; 2019 Nov; 101(8):596-601. PubMed ID: 31219316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
    Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
    Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS).
    Casasanta N; Patel R; Raymond S; Kier MW; Blanter J; Sohval S; Hovstadius M; Wu C; Zimmerman B; Cascetta K; Bagiella E; Tiersten A
    Clin Breast Cancer; 2024 Oct; 24(7):585-596. PubMed ID: 38971641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.
    Chin-Lenn L; De Boer RH; Segelov E; Marx GM; Hughes TM; McCarthy NJ; White SC; Foo SS; Rutovitz JJ; Della-Fiorentina S; Jennens R; Antill YC; Tsoi D; Cronk MF; Lombard JM; Kiely BE; Chirgwin JH; Gorelik A; Mann GB
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):410-416. PubMed ID: 30270527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
    Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
    Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study.
    Nam G; Singh K; Lopresti ML; Ouseph MM; Wang LJ; Wang Y
    Technol Cancer Res Treat; 2021; 20():15330338211035037. PubMed ID: 34696631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
    Wang SY; Chen T; Dang W; Mougalian SS; Evans SB; Gross CP
    J Natl Compr Canc Netw; 2019 Jan; 17(1):39-46. PubMed ID: 30659128
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of introduction of Oncotype DX
    Green N; Al-Allak A; Fowler C
    Ann R Coll Surg Engl; 2019 Jan; 101(1):55-59. PubMed ID: 30322288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.
    Loggie J; Barnes PJ; Carter MD; Rayson D; Bethune GC
    Breast; 2024 Jun; 75():103715. PubMed ID: 38520994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.